Since ELISA can give quantitative results, an agreement between ELISA and IP would provide additional information of interest as not only the presence but also levels of anti-TIF1-gamma autoantibodies may be of importance to predict cancer risk or recurrence of cancer in patients with DM [8]. This evidence concerns the gene TRIM33 and dermatomyositis.